REDWOOD CITY, Calif., July 31, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2013.
Product revenue was $63.7 million in the second quarter of 2013, compared with $57.2 million for the second quarter of 2012, an increase of 11 percent. Total revenue for the second quarter of 2013 increased to $63.7 million, compared with $57.6 million in the second quarter of 2012.
International product revenue grew by 58 percent to $9.2 million compared to the same period in 2012 and represented 14 percent of product revenue.
Net loss in the second quarter of 2013 was $3.0 million, compared with net income of $1.8 million in the second quarter of 2012. Basic and diluted net loss per share applicable to common stockholders was $0.10 for the second quarter of 2013, compared with a basic and diluted net income per share of $0.06 for the same period in 2012.
"In the second quarter, we delivered strong results with 11 percent year-over-year growth in product revenue and 9 percent growth in tests delivered, highlighted by higher U.S. invasive breast cancer penetration and the continued success of our international expansion," said Kim Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. "Importantly, we achieved two major milestones toward further business diversification and long-term growth with the successful launch of the Oncotype DX prostate cancer test, our third product franchise, and Medicare reimbursement for our DCIS Score."Additional Second Quarter 2013 and Six Months Ended Jun
|SOURCE Genomic Health, Inc.|
Copyright©2012 PR Newswire.
All rights reserved